Is this your brand? Sign in to claim ownership.

Sign in to claim this brand

Accelerate Diagnostics, Inc.

US

Last updated May 30, 2026

Information

Country
US
Address
—
Website
—
LinkedIn
—
Facebook
—
Email
—
Phone
—
PRRC Contact
—
EUDAMED SRN
—
FDA FEI Number
—
DUNS Number
186328670

Catalogue (10)

DeviceModel / ReferenceRegistriesClassStatus
Accelerate Pheno™ System 10301008
FDA UDI
Class IIActive
Accelerate PhenoTest® BC AST QC test 10107158
FDA UDI
Class IIActive
Accelerate PhenoTest BC ID QC test 10105158
FDA UDI
Class IIActive
Accelerate PhenoTest™ BC Kit 10101018
FDA UDI
Class IIActive
Accelerate Pheno™ System 10401008
FDA UDI
Class IIActive
Accelerate PhenoTest BC kit 10104018
FDA UDI
Class IIActive
Accelerate PhenoTest® BC kit 10102018
FDA UDI
Class IIActive
Accelerate PhenoTest BC AST QC test 10106158
FDA UDI
Class IIActive
Accelerate Pheno System, Accelerate PhenoTest BC Kit K192665
FDA 510(k)
Class IIActive
Accelerate Arc System K240854
FDA 510(k)
Class IIActive

Related Companies

Authorised Representatives

No authorised representatives on record.

Importers

Not available yet.

Notified Bodies

Not available yet.

Authorities

Not available yet.

FDA Recalls (4)

Recalls reported by this firm to the FDA. Listed at company level — FDA recall records don't identify a specific catalogue device.

DateRecall No.ClassStatusReason
Oct 17, 2022Z-0345-2023—open, classified

Due improperly formulated and released bulk lot of fluorescence in situ hybridization (FISH) probes resulting in false positive identification results for Staphylococcus aureus and Streptococcus spp.

Oct 17, 2022Z-0346-2023—open, classified

Due improperly formulated and released bulk lot of fluorescence in situ hybridization (FISH) probes resulting in false positive identification results for Staphylococcus aureus and Streptococcus spp.

Mar 14, 2018Z-1529-2018—terminated

The kits may produce an elevated rate of false positive calls for the Staphylococcus aureus identification probe (SAU).

Mar 13, 2017Z-1065-2019—terminated

Rare isolates of Enterobacteriaceae may generate a susceptible meropenem Minimum Inhibitory Concentration (MIC) using the affected device and a resistant result by broth microdilution. In order to mitigate any risk associated with these rare isolates, the firm has implemented an Expert Rule that suppresses the meropenem result for isolates that display a profile consistent with those that generated a false-susceptible result. The firm has responded to this risk by implementing a set of suppression rules, in a software update, to prevent incorrect results.